Global

Brazil was the last country to enter the fiscal crisis, but also the first to exit. And with a burgeoning middle class and a staunch commitment to national development, its pharmaceutical future is now.

Brazilian industry is learning to spread its pharma manufacturing around more.

Astellas makes its presence felt in Brazil.

French-based Besins is a relatively new entrant to the Brazilian pharma market.

With Europe's economic troubles causing domestic profitability concerns, established pharmaceutical companies may need look to emerging markets for outsourcing partners.

The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized.

Torrent's affiliate in Brazil has become the India-based company's biggest.

Biominas helps foster the development of biotech-related businesses in Brazil.

Hungary's high-quality infrsatructure, highly skilled labor force, and central geographic location have turned the country into an attractive destination for investment.

William Looney looks at how Big Pharma is attempting to bridge the emerging markets' widening cancer divide.

The use and study of DDW by the Hungarian medical community

A quick chat with CMO of Assign Group Dr. Kata Mazalin

The challenge for 2012 is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap.

A turbulent year is ahead for European pharma, while EFPIA's Director General begins to rethink its approach to new science.

The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales.

It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?

Even as the global economic roller coaster affects one of the country's dearest public institutions-the National Health Service-there is still reason for optimism in these times of austerity

GM's and investors find consensus in identifying innovation and productivity emerging from academia and small startups

Will big investments in infrastructure carry the day in positioning China as a global drug innovation powerhouse?

The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver?

The pharmaceutical industry in Britain is a key sesctor in the full economic recovery of the country

The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item, writes William Looney.

Will the structure and ambiguity of Germany's new medicines pricing system bring a halt to new drug launches in Europe's largest market?

The EC's latest proposals have thrown water on Europe's firey Direct-to-Consumer advertising debate. But is it enough to keep the flames at bay?

Richard Pops, Chief Executive Officer of Alkermes, explains how the company has established itself as a global, Irish-based firm.

GxP Cloud - business enablement for Life Sciences

Y.K. Hamied, PhD, Chairman, Cipla

Success in the emerging markets depends significantly on navigating the myths and mental traps.

Sir Michael Rawlins, Chairman of the UK National Institute for Health and Clinical Excellence

Garbo gets it ...